ZA200608738B - Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists - Google Patents
Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists Download PDFInfo
- Publication number
- ZA200608738B ZA200608738B ZA200608738A ZA200608738A ZA200608738B ZA 200608738 B ZA200608738 B ZA 200608738B ZA 200608738 A ZA200608738 A ZA 200608738A ZA 200608738 A ZA200608738 A ZA 200608738A ZA 200608738 B ZA200608738 B ZA 200608738B
- Authority
- ZA
- South Africa
- Prior art keywords
- ethyl
- amino
- phenyl
- chloro
- carbonyl
- Prior art date
Links
- 239000003446 ligand Substances 0.000 title claims description 30
- 101150109738 Ptger4 gene Proteins 0.000 title claims description 16
- 239000002464 receptor antagonist Substances 0.000 title claims description 16
- 229940044551 receptor antagonist Drugs 0.000 title claims description 16
- 150000003839 salts Chemical class 0.000 claims description 18
- -1 3,5-dimethyl-4-phenyl-1H-pyrazol-1 -yl Chemical group 0.000 claims description 15
- 208000002193 Pain Diseases 0.000 claims description 15
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Natural products CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 14
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 claims description 13
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 11
- 239000002253 acid Substances 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 229960002870 gabapentin Drugs 0.000 claims description 5
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 claims description 4
- 239000003814 drug Substances 0.000 claims description 4
- JXEHXYFSIOYTAH-SFYZADRCSA-N imagabalin Chemical compound CCC[C@@H](C)C[C@H](N)CC(O)=O JXEHXYFSIOYTAH-SFYZADRCSA-N 0.000 claims description 4
- AYXYPKUFHZROOJ-ZETCQYMHSA-N pregabalin Chemical compound CC(C)C[C@H](CN)CC(O)=O AYXYPKUFHZROOJ-ZETCQYMHSA-N 0.000 claims description 4
- 229960001233 pregabalin Drugs 0.000 claims description 4
- RGFRGRZSMVXTLF-ONGXEEELSA-N (2s,4s)-4-[(3-fluorophenyl)methyl]pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1CC1=CC=CC(F)=C1 RGFRGRZSMVXTLF-ONGXEEELSA-N 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims description 3
- 208000004296 neuralgia Diseases 0.000 claims description 3
- 208000021722 neuropathic pain Diseases 0.000 claims description 3
- LUANXJIOUGKVRZ-UWVGGRQHSA-N (2s,4s)-4-(3-chlorophenoxy)pyrrolidine-2-carboxylic acid Chemical compound C1N[C@H](C(=O)O)C[C@@H]1OC1=CC=CC(Cl)=C1 LUANXJIOUGKVRZ-UWVGGRQHSA-N 0.000 claims description 2
- KKXFMWXZXDUYBF-BDAKNGLRSA-N (3s,5r)-3-(aminomethyl)-5-methyloctanoic acid Chemical compound CCC[C@@H](C)C[C@H](CN)CC(O)=O KKXFMWXZXDUYBF-BDAKNGLRSA-N 0.000 claims description 2
- GUEQOLSQPOTTME-RQJHMYQMSA-N (3s,5r)-3-amino-5-methylheptanoic acid Chemical compound CC[C@@H](C)C[C@H](N)CC(O)=O GUEQOLSQPOTTME-RQJHMYQMSA-N 0.000 claims description 2
- XKWDZEJCUWTBOM-BDAKNGLRSA-N (3s,5r)-3-amino-5-methylnonanoic acid Chemical compound CCCC[C@@H](C)C[C@H](N)CC(O)=O XKWDZEJCUWTBOM-BDAKNGLRSA-N 0.000 claims description 2
- 206010065390 Inflammatory pain Diseases 0.000 claims description 2
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 claims description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims 16
- 239000005711 Benzoic acid Substances 0.000 claims 8
- 235000010233 benzoic acid Nutrition 0.000 claims 8
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims 8
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 6
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- FULSIHOOFUQXTB-UHFFFAOYSA-N (2-chlorophenyl)sulfonylcarbamic acid Chemical compound OC(=O)NS(=O)(=O)C1=CC=CC=C1Cl FULSIHOOFUQXTB-UHFFFAOYSA-N 0.000 claims 2
- VATAIZDYZPAXOX-UHFFFAOYSA-N (4-methylphenyl)sulfonylcarbamic acid Chemical compound CC1=CC=C(S(=O)(=O)NC(O)=O)C=C1 VATAIZDYZPAXOX-UHFFFAOYSA-N 0.000 claims 2
- KHBQMWCZKVMBLN-UHFFFAOYSA-N Benzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC=C1 KHBQMWCZKVMBLN-UHFFFAOYSA-N 0.000 claims 2
- 238000009109 curative therapy Methods 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 238000002638 palliative care Methods 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 238000011321 prophylaxis Methods 0.000 claims 2
- VRSJQMXCCLVETK-UHFFFAOYSA-N 1-[2-[4-(2-ethyl-4-phenylimidazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC(C=2C=CC=CC=2)=CN1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 VRSJQMXCCLVETK-UHFFFAOYSA-N 0.000 claims 1
- KFDAZUZDUCNSCO-UHFFFAOYSA-N 1-[2-[4-(3,5-dimethyl-4-phenylpyrazol-1-yl)phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CC1=NN(C=2C=CC(CCNC(=O)NS(=O)(=O)C=3C=CC(C)=CC=3)=CC=2)C(C)=C1C1=CC=CC=C1 KFDAZUZDUCNSCO-UHFFFAOYSA-N 0.000 claims 1
- GFMMZVFKQDQZHJ-UHFFFAOYSA-N 1-[2-[4-[2-ethyl-5-(2-hydroxypropan-2-yl)benzimidazol-1-yl]phenyl]ethyl]-3-(4-methylphenyl)sulfonylurea Chemical compound CCC1=NC2=CC(C(C)(C)O)=CC=C2N1C(C=C1)=CC=C1CCNC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 GFMMZVFKQDQZHJ-UHFFFAOYSA-N 0.000 claims 1
- IFQJIRWSTAXGLB-UHFFFAOYSA-N 2-[4-[2-(2-methylpropyl)-4-phenylimidazol-1-yl]phenyl]ethyl n-(2-chlorophenyl)sulfonylcarbamate Chemical compound CC(C)CC1=NC(C=2C=CC=CC=2)=CN1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=CC=C1Cl IFQJIRWSTAXGLB-UHFFFAOYSA-N 0.000 claims 1
- VFGIXMWNVHDPQH-UHFFFAOYSA-N 2-[4-[5,7-dimethyl-2-(methylamino)imidazo[4,5-b]pyridin-3-yl]phenyl]ethyl n-(4-methylphenyl)sulfonylcarbamate Chemical compound CNC1=NC2=C(C)C=C(C)N=C2N1C(C=C1)=CC=C1CCOC(=O)NS(=O)(=O)C1=CC=C(C)C=C1 VFGIXMWNVHDPQH-UHFFFAOYSA-N 0.000 claims 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 claims 1
- MOEZPHHJIZLEKX-UHFFFAOYSA-N 3-[[1-(aminomethyl)cyclohexyl]methyl]-2h-1,2,4-oxadiazol-5-one Chemical compound N=1OC(=O)NC=1CC1(CN)CCCCC1 MOEZPHHJIZLEKX-UHFFFAOYSA-N 0.000 claims 1
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 1
- KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims 1
- JYZIHLWOWKMNNX-UHFFFAOYSA-N benzimidazole Chemical compound C1=C[CH]C2=NC=NC2=C1 JYZIHLWOWKMNNX-UHFFFAOYSA-N 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- 125000000217 alkyl group Chemical group 0.000 description 65
- 125000004432 carbon atom Chemical group C* 0.000 description 64
- 125000003118 aryl group Chemical group 0.000 description 33
- 125000001072 heteroaryl group Chemical group 0.000 description 27
- 125000003545 alkoxy group Chemical group 0.000 description 22
- 125000000753 cycloalkyl group Chemical group 0.000 description 14
- 125000001424 substituent group Chemical group 0.000 description 14
- 125000005843 halogen group Chemical group 0.000 description 12
- 239000011575 calcium Substances 0.000 description 11
- 125000004093 cyano group Chemical group *C#N 0.000 description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 9
- 229910052717 sulfur Inorganic materials 0.000 description 9
- 150000001875 compounds Chemical class 0.000 description 8
- 125000001153 fluoro group Chemical group F* 0.000 description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 8
- 229910052757 nitrogen Inorganic materials 0.000 description 8
- 229910052760 oxygen Inorganic materials 0.000 description 8
- 125000004656 alkyl sulfonylamino group Chemical group 0.000 description 7
- 125000004414 alkyl thio group Chemical group 0.000 description 7
- 125000002947 alkylene group Chemical group 0.000 description 7
- 125000005842 heteroatom Chemical group 0.000 description 7
- 125000002950 monocyclic group Chemical group 0.000 description 7
- 125000004430 oxygen atom Chemical group O* 0.000 description 7
- 229910052739 hydrogen Inorganic materials 0.000 description 6
- 239000001257 hydrogen Substances 0.000 description 6
- 125000004434 sulfur atom Chemical group 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 5
- 125000003342 alkenyl group Chemical group 0.000 description 5
- 125000000304 alkynyl group Chemical group 0.000 description 5
- 125000004397 aminosulfonyl group Chemical group NS(=O)(=O)* 0.000 description 5
- 125000004429 atom Chemical group 0.000 description 5
- 125000002619 bicyclic group Chemical group 0.000 description 5
- 125000001188 haloalkyl group Chemical group 0.000 description 5
- 125000004433 nitrogen atom Chemical group N* 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 125000003277 amino group Chemical group 0.000 description 4
- 125000003710 aryl alkyl group Chemical group 0.000 description 4
- 125000004076 pyridyl group Chemical group 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 125000003282 alkyl amino group Chemical group 0.000 description 3
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 125000000392 cycloalkenyl group Chemical group 0.000 description 3
- 206010015037 epilepsy Diseases 0.000 description 3
- 125000004438 haloalkoxy group Chemical group 0.000 description 3
- 150000002460 imidazoles Chemical class 0.000 description 3
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108090000312 Calcium Channels Proteins 0.000 description 2
- 102000003922 Calcium Channels Human genes 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 2
- 125000002431 aminoalkoxy group Chemical group 0.000 description 2
- 125000006615 aromatic heterocyclic group Chemical group 0.000 description 2
- 125000001589 carboacyl group Chemical group 0.000 description 2
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 2
- 125000002768 hydroxyalkyl group Chemical group 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 125000004043 oxo group Chemical group O=* 0.000 description 2
- 125000005476 oxopyrrolidinyl group Chemical group 0.000 description 2
- 125000005936 piperidyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- GWLVNOAPYJMHQV-BWZBUEFSSA-N (3r,4r,5r)-3-amino-4,5-dimethylheptanoic acid Chemical compound CC[C@@H](C)[C@@H](C)[C@H](N)CC(O)=O GWLVNOAPYJMHQV-BWZBUEFSSA-N 0.000 description 1
- KRZJRNZICWNMOA-GXSJLCMTSA-N (3s,4r)-4,8-dihydroxy-3-methoxy-3,4-dihydro-2h-naphthalen-1-one Chemical compound C1=CC=C2[C@@H](O)[C@@H](OC)CC(=O)C2=C1O KRZJRNZICWNMOA-GXSJLCMTSA-N 0.000 description 1
- 125000006652 (C3-C12) cycloalkyl group Chemical group 0.000 description 1
- 125000006618 5- to 10-membered aromatic heterocyclic group Chemical group 0.000 description 1
- 208000004454 Hyperalgesia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000001294 Nociceptive Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 241000812633 Varicus Species 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000004442 acylamino group Chemical group 0.000 description 1
- 125000005236 alkanoylamino group Chemical group 0.000 description 1
- 125000004450 alkenylene group Chemical group 0.000 description 1
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004691 alkyl thio carbonyl group Chemical group 0.000 description 1
- 125000004419 alkynylene group Chemical group 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003491 cAMP production Effects 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 125000002993 cycloalkylene group Chemical group 0.000 description 1
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002066 eicosanoids Chemical class 0.000 description 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical class NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 1
- 239000011440 grout Substances 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- 150000002367 halogens Chemical class 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 1
- 229940072228 neurontin Drugs 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
- 230000003040 nociceptive effect Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000001175 peptic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000000843 phenylene group Chemical group C1(=C(C=CC=C1)*)* 0.000 description 1
- 239000000651 prodrug Substances 0.000 description 1
- 229940002612 prodrug Drugs 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 150000003217 pyrazoles Chemical class 0.000 description 1
- 125000006413 ring segment Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 208000009935 visceral pain Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/10—Antiepileptics; Anticonvulsants for petit-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A61P25/12—Antiepileptics; Anticonvulsants for grand-mal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56386304P | 2004-04-20 | 2004-04-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
ZA200608738B true ZA200608738B (en) | 2008-06-25 |
Family
ID=34962978
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ZA200608738A ZA200608738B (en) | 2004-04-20 | 2006-10-19 | Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists |
Country Status (16)
Country | Link |
---|---|
US (1) | US20090036495A1 (ja) |
EP (1) | EP1740211A2 (ja) |
JP (1) | JP2007533723A (ja) |
KR (1) | KR20070000495A (ja) |
CN (1) | CN1946391A (ja) |
AR (1) | AR049029A1 (ja) |
AU (1) | AU2005235248A1 (ja) |
BR (1) | BRPI0509993A (ja) |
CA (1) | CA2563356A1 (ja) |
IL (1) | IL178609A0 (ja) |
MX (1) | MXPA06012172A (ja) |
NO (1) | NO20065271L (ja) |
RU (1) | RU2006137076A (ja) |
TW (1) | TW200539861A (ja) |
WO (1) | WO2005102389A2 (ja) |
ZA (1) | ZA200608738B (ja) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI0934061T1 (en) | 1996-07-24 | 2003-10-31 | Warner-Lambert Company Llc | Isobutylgaba and its derivatives for the treatment of pain |
CA2613522A1 (en) | 2005-06-27 | 2007-01-04 | Exelixis, Inc. | Imidazole based lxr modulators |
EP2025672B1 (en) * | 2006-05-31 | 2013-09-18 | Daiichi Sankyo Company, Limited | Process for producing 1-carbamoyl-3,7-dioxo-1,4-diazepane compounds |
AU2007283404B2 (en) * | 2006-08-11 | 2013-04-18 | Merck Canada Inc. | Thiophenecarboxamide derivatives as EP4 receptor ligands |
US8598355B2 (en) * | 2008-05-14 | 2013-12-03 | Astellas Pharma Inc. | Amide compound |
CA2754702C (en) * | 2009-04-22 | 2016-06-07 | Yukinori Take | Selective ep4 antagonistic substance for treatment of cancer |
CA2789665C (en) * | 2010-02-22 | 2020-06-16 | Raqualia Pharma Inc. | Use of ep4 receptor antagonists in the treatment of il-23 mediated diseases |
UA115576C2 (uk) | 2012-12-06 | 2017-11-27 | Байєр Фарма Акцієнгезелльшафт | Похідні бензимідазолу як антагоністи ер4 |
CN107496421A (zh) * | 2013-03-19 | 2017-12-22 | 株式会社AskAt | Ep4受体拮抗剂在软骨疾病的治疗中的用途 |
US10391086B2 (en) | 2013-03-19 | 2019-08-27 | Askat Inc. | Use of EP4 receptor antagonists in the treatment of cartilage disease |
MA38661A1 (fr) | 2013-06-27 | 2017-03-31 | Pfizer | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine |
TW201607943A (zh) | 2013-12-19 | 2016-03-01 | 拜耳製藥公司 | 作為ep4配體之新穎苯并咪唑衍生物 |
CA2941008C (en) * | 2014-03-06 | 2022-07-26 | Aratana Therapeutics, Inc. | Compositions of grapiprant and methods for using the same |
US10342785B2 (en) | 2016-11-04 | 2019-07-09 | Askat Inc. | Use of EP4 receptor antagonists for the treatment of NASH-associated liver cancer |
WO2018162562A1 (en) | 2017-03-10 | 2018-09-13 | Bayer Pharma Aktiengesellschaft | Use of an ep4 antagonist for the treatment of inflammatory pain |
WO2019038156A1 (en) | 2017-08-22 | 2019-02-28 | Bayer Pharma Aktiengesellschaft | USE OF AN EP4 ANTAGONIST FOR THE TREATMENT OF ARTHRITIS |
US10239885B1 (en) * | 2018-06-18 | 2019-03-26 | Avista Pharma Solutions, Inc. | Compound 1-[2-[4-(2-ethyl-6,8-dimethylimidazo[1,2-α]pyrazin-3-yl)phenyl]ethyl]-3-(p-tolylsulfonyl)urea as a prostaglandin EP4 receptor antagonist |
EP3820469A4 (en) * | 2018-07-11 | 2022-04-13 | Arrys Therapeutics, Inc. | EP4 INHIBITORS AND USE THEREOF |
US11254675B2 (en) * | 2019-08-12 | 2022-02-22 | Cadila Healthcare Limited | Process for preparation of grapiprant |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2206119C (en) * | 1994-12-12 | 2008-05-13 | Omeros Medical Systems, Inc. | Irrigation solution and method for inhibition of pain, inflammation and spasm |
TWI249520B (en) * | 1998-07-15 | 2006-02-21 | Ono Pharmaceutical Co | 5-Thia-omega-substituted phenyl prostaglandin E derivatives, method for producing the same and medicines containing the same as the active ingredient |
EP1202730B1 (en) * | 1999-08-10 | 2004-08-04 | Glaxo Group Limited | Use of ep4 receptor ligands in the treatment of neuropathic pain |
HN2001000224A (es) * | 2000-10-19 | 2002-06-13 | Pfizer | Compuestos de imidazol condensado con arilo o heteroarilo como agentes anti - inflamatorios y analgesicos. |
GB0030541D0 (en) * | 2000-12-14 | 2001-01-31 | Glaxo Group Ltd | Medical uses |
GB0031295D0 (en) * | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Naphthalene derivatives |
GB0031302D0 (en) * | 2000-12-21 | 2001-01-31 | Glaxo Group Ltd | Napthalene derivatives |
HUP0400183A2 (hu) * | 2001-06-11 | 2004-07-28 | Xenoport Inc. | Gaba-analóg prodrugok csökkentett toxicitású orális dózisformái |
-
2005
- 2005-04-08 US US11/568,152 patent/US20090036495A1/en not_active Abandoned
- 2005-04-08 RU RU2006137076/15A patent/RU2006137076A/ru not_active Application Discontinuation
- 2005-04-08 WO PCT/IB2005/000935 patent/WO2005102389A2/en active Application Filing
- 2005-04-08 CA CA002563356A patent/CA2563356A1/en not_active Abandoned
- 2005-04-08 AU AU2005235248A patent/AU2005235248A1/en not_active Abandoned
- 2005-04-08 EP EP05718401A patent/EP1740211A2/en not_active Withdrawn
- 2005-04-08 KR KR1020067021753A patent/KR20070000495A/ko not_active Application Discontinuation
- 2005-04-08 CN CNA2005800135012A patent/CN1946391A/zh active Pending
- 2005-04-08 MX MXPA06012172A patent/MXPA06012172A/es unknown
- 2005-04-08 JP JP2007508991A patent/JP2007533723A/ja not_active Withdrawn
- 2005-04-08 BR BRPI0509993-5A patent/BRPI0509993A/pt not_active IP Right Cessation
- 2005-04-19 TW TW094112340A patent/TW200539861A/zh unknown
- 2005-04-20 AR ARP050101557A patent/AR049029A1/es not_active Application Discontinuation
-
2006
- 2006-10-15 IL IL178609A patent/IL178609A0/en unknown
- 2006-10-19 ZA ZA200608738A patent/ZA200608738B/en unknown
- 2006-11-16 NO NO20065271A patent/NO20065271L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
US20090036495A1 (en) | 2009-02-05 |
RU2006137076A (ru) | 2008-04-27 |
WO2005102389A2 (en) | 2005-11-03 |
CA2563356A1 (en) | 2005-11-03 |
JP2007533723A (ja) | 2007-11-22 |
WO2005102389A9 (en) | 2009-04-30 |
AR049029A1 (es) | 2006-06-21 |
BRPI0509993A (pt) | 2007-10-16 |
CN1946391A (zh) | 2007-04-11 |
NO20065271L (no) | 2006-12-12 |
TW200539861A (en) | 2005-12-16 |
KR20070000495A (ko) | 2007-01-02 |
WO2005102389A3 (en) | 2006-08-17 |
EP1740211A2 (en) | 2007-01-10 |
MXPA06012172A (es) | 2007-01-17 |
IL178609A0 (en) | 2007-02-11 |
AU2005235248A1 (en) | 2005-11-03 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA200608738B (en) | Combinations comprising alpha-2-delta ligands and EP4 receptor antagonists | |
CA3053991A1 (en) | Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases | |
KR20110028651A (ko) | (a) 포스포이노시타이드 3-키나제 억제제 및 (b) ras/raf/mek 경로의 조절제의 조합물 | |
NZ556275A (en) | Combination of renin and NEP inhibitors for treating diseases mediated by angiotenson II and NEP activity | |
WO2007149283B1 (en) | Use of kw-3902 for achieving diuresis in patients with congestive heart failure and acute fluid overload | |
Kshirsagar et al. | DPP IV inhibitors: successes, failures and future prospects | |
MXPA05007103A (es) | Combinacion farmaceutica para la prevencion o tratamiento de enfermedades cardiovasculares, cardiopulmonares, pulmonares o renales. | |
WO2004000327A1 (ja) | 2型糖尿病治療剤 | |
EP2059245A1 (en) | Bifeprunox doses for treating schizophrenia | |
DK3027183T3 (en) | SELECTIVE AT2 RECEPTOR AGONISTS FOR USING CACKSY TREATMENT | |
US20180333398A1 (en) | Method of weight reduction | |
MX2011009506A (es) | Antagonista del receptor mineralcorticoide y metodos de uso. | |
KR20070053239A (ko) | 사구체 질환 치료제 | |
JP7193455B2 (ja) | 心血管状態におけるインスリンデグルデク | |
EP1907004A2 (en) | Combination of a renin inhibitor and an insulin secretion enhancer or an insulin sensitizer | |
US20060079579A1 (en) | Combinations of valsartan with cox-2 inhibitors | |
AU2011270133A1 (en) | Sustained-release therapeutic agent for hypertension and renal dysfunction | |
Pema | Lesinurad sodium | |
US20190371469A1 (en) | Method of Identifying a Subgroup of Patients Suffering from DcSSc which Benefits from a Treatment with sGC Stimulators and sGC Activators in a Higher Degree than a Control Group | |
Sharma | Hypertension therapeutics update: a brief clinical summary on azilsartan, cilnidipine and nebivolol | |
AU2016206292B2 (en) | A method of improving liver function | |
Sternlicht et al. | Hypertension and Chronic Kidney | |
WO2018012634A1 (ja) | 不飽和複素5員環含有化合物を含有する肺高血圧症の予防又は治療剤 | |
KR101579656B1 (ko) | 프라바스타틴과 발사르탄을 포함하는 약학 조성물 | |
AU2004226517A1 (en) | Use of atii antagonist for the treatment or prevention of metabolic syndrome |